In the last few years, the type 2 sodium glucose co-transporters (SGLT2) have been the subject of particular attention as a new, potent group of anti-diabetic drugs. SGLT2 inhibitors block glucose reabsorption in the kidneys, which prompts urinary excretion of glucose and results in lowering of its plasma levels. Although this group of medications is still under investigation, their efficacy in the treatment of type 2 diabetes mellitus (T2D) is very promising, with some of these inhibitors currently undergoing clinical trials.